{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:55:02Z","timestamp":1790096102628,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017699","name":"Galecto Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejphar.2024.177077","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T17:11:48Z","timestamp":1731172308000},"page":"177077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver"],"prefix":"10.1016","volume":"985","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-4141","authenticated-orcid":false,"given":"Alison C.","family":"MacKinnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5551-6536","authenticated-orcid":false,"given":"Duncan C.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Roper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Holyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mabbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-9522","authenticated-orcid":false,"given":"Ulf J.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakon","family":"Leffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Schambye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-9438","authenticated-orcid":false,"given":"Robert J.","family":"Slack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.177077_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.744518","article-title":"Role of galectins in the liver diseases: a systematic review and meta-analysis","volume":"8","author":"An","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2024.177077_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00280-023-04513-y","article-title":"Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants","volume":"91","author":"Aslanis","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.177077_bib3","first-page":"41","article-title":"Serum CHI3L1 as a biomarker for non-invasive diagnosis of liver fibrosis","volume":"33","author":"Bao","year":"2022","journal-title":"Discov. Med."},{"key":"10.1016\/j.ejphar.2024.177077_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0092-8674(94)90498-7","article-title":"Galectins: a family of animal beta-galactoside-binding lectins","volume":"76","author":"Barondes","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2024.177077_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107300","article-title":"Defining the mechanism of galectin-3-mediated TGF-\u03b21 activation and its role in lung fibrosis","volume":"300","author":"Calver","year":"2024","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.177077_bib6","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1111\/liv.15326","article-title":"Galectin-3 is overexpressed in advanced cirrhosis and predicts post-liver transplant infectious complications","volume":"42","author":"Cervantes-Alvarez","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2024.177077_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI200522675","article-title":"Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair","volume":"115","author":"Duffield","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2024.177077_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add8945","article-title":"Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation","volume":"8","author":"Fabre","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ejphar.2024.177077_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-0036-1586228","article-title":"The role of plasminogen activator inhibitor type-1 in fibrosis","volume":"43","author":"Flevaris","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.ejphar.2024.177077_bib10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2024.177077_bib11","first-page":"6239","article-title":"The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells","volume":"59","author":"Gong","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2024.177077_bib12","first-page":"669","article-title":"Galectin-3 concentration in liver diseases","volume":"45","author":"Gudowska","year":"2015","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.ejphar.2024.177077_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","article-title":"Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis","volume":"172","author":"Henderson","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2024.177077_bib14","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejphar.2024.177077_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02559-2020","article-title":"Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Hirani","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2024.177077_bib16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/gutjnl-2013-306290","article-title":"Galectin-3 regulates hepatic progenitor cell expansion during liver injury","volume":"64","author":"Hsieh","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2024.177077_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00798.x","article-title":"Galectin-3 regulates T-cell functions","volume":"230","author":"Hsu","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2024.177077_bib18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/B:GLYC.0000014080.95829.52","article-title":"Regulation of cellular homeostasis by galectins","volume":"19","author":"Hsu","year":"2002","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.ejphar.2024.177077_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3227957","article-title":"Diagnostic value of serum chitinase-3-like protein 1 for liver fibrosis: a meta-analysis","volume":"2022","author":"Huang","year":"2022","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejphar.2024.177077_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.slasd.2023.03.005","article-title":"Evaluating the affinity and kinetics of small molecule glycomimetics for human and mouse galectin-3 using surface plasmon resonance","volume":"28","author":"Kim","year":"2023","journal-title":"SLAS Discov"},{"key":"10.1016\/j.ejphar.2024.177077_bib21","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s42003-021-02616-x","article-title":"Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system","volume":"4","author":"Kostrzewski","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejphar.2024.177077_bib22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/glycob\/cwab072","article-title":"Molecular mechanism of interspecies differences in the binding affinity of TD139 to Galectin-3","volume":"31","author":"Kumar","year":"2021","journal-title":"Glycobiology"},{"key":"10.1016\/j.ejphar.2024.177077_bib23","doi-asserted-by":"crossref","first-page":"21751","DOI":"10.1074\/jbc.C112.358002","article-title":"Ligand induced galectin-3 protein self-association","volume":"287","author":"Lepur","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.177077_bib24","article-title":"GULLIVER-2: a phase 2, randomised trial of GB1211 (selvigaltin) \u2013 an oral galectin-3 inhibitor for the treatment of Child-Pugh B cirrhosis","author":"Lindmark","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2024.177077_bib25","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1021\/acs.jmedchem.2c00517","article-title":"Identification of monosaccharide derivatives as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2024.177077_bib26","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.4049\/jimmunol.180.4.2650","article-title":"Regulation of alternative macrophage activation by galectin-3","volume":"180","author":"MacKinnon","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2024.177077_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-\u03b21-driven lung fibrosis by galectin-3","volume":"185","author":"Mackinnon","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejphar.2024.177077_bib28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/glycob\/cwt006","article-title":"Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"23","author":"MacKinnon","year":"2013","journal-title":"Glycobiology"},{"key":"10.1016\/j.ejphar.2024.177077_bib29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14728222.2023.2258280","article-title":"Galectin-3: therapeutic targeting in liver disease","volume":"27","author":"Mackinnon","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejphar.2024.177077_bib30","article-title":"S89 Ex vivo studies of the gal-3-fibrosome hypothesis in IPF and non-fibrotic control lung tissue and myofibroblasts","volume":"74","author":"Miah","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.ejphar.2024.177077_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/bs.ircmb.2022.04.006","article-title":"Macrophages as key regulators of liver health and disease","volume":"368","author":"Papachristoforou","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.ejphar.2024.177077_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.1102109","article-title":"Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis","volume":"306","author":"Partridge","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2024.177077_bib33","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.2147\/IJGM.S364602","article-title":"The value of serum CHI3L1 for the diagnosis of chronic liver diseases","volume":"15","author":"Qiu","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.ejphar.2024.177077_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1471-4906(02)02232-9","article-title":"Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?","volume":"23","author":"Rabinovich","year":"2002","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejphar.2024.177077_bib35","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.177077_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/alz.060393","article-title":"Potential reversal of alzheimer's disease pathology by antibody TB006 targeting galectin\u20103, the root cause of oligomerization of amyloid proteins","volume":"18","author":"Rasool","year":"2022","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.ejphar.2024.177077_bib37","doi-asserted-by":"crossref","first-page":"35079","DOI":"10.1074\/jbc.M109.098160","article-title":"Mutational tuning of galectin-3 specificity and biological function","volume":"285","author":"Salomonsson","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.177077_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19020379","article-title":"Galectin-3: one molecule for an alphabet of diseases, from A to Z","volume":"19","author":"Sciacchitano","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177077_bib39","article-title":"Galectin-3 inhibition reduces fibrotic scarring and promotes functional recovery after spinal cord injury in mice","author":"Shan","year":"2024","journal-title":"Lancet Preprints"},{"key":"10.1016\/j.ejphar.2024.177077_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2020.105881","article-title":"The therapeutic potential of galectin-3 inhibition in fibrotic disease","volume":"130","author":"Slack","year":"2021","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejphar.2024.177077_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ab.2004.06.042","article-title":"Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions","volume":"334","author":"S\u00f6rme","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejphar.2024.177077_bib42","doi-asserted-by":"crossref","first-page":"13318","DOI":"10.1074\/jbc.M116.721464","article-title":"Low or No inhibitory potency of the canonical galectin carbohydrate-binding site by pectins and galactomannans","volume":"291","author":"Stegmayr","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.177077_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075361","article-title":"Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.177077_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083481","article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.177077_bib45","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1016\/S2214-109X(22)00047-X","article-title":"Chronic liver diseases must be reduced worldwide: it is time to act","volume":"10","author":"Vento","year":"2022","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.ejphar.2024.177077_bib46","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/0008-5472.CAN-18-2244","article-title":"An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade","volume":"79","author":"Vuong","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2024.177077_bib47","doi-asserted-by":"crossref","first-page":"18419","DOI":"10.1016\/S0021-9258(18)55075-4","article-title":"Carbohydrate-binding protein 35 (Mac-2), a laminin-binding lectin, forms functional dimers using cysteine 186","volume":"266","author":"Woo","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.177077_bib48","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1016\/j.febslet.2013.10.034","article-title":"Regulation of galectin-3-induced apoptosis of Jurkat cells by both O-glycans and N-glycans on CD45","volume":"87","author":"Xue","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2024.177077_bib49","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/S1462399408000719","article-title":"Galectins: structure, function and therapeutic potential","volume":"10","author":"Yang","year":"2008","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejphar.2024.177077_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.909455","article-title":"The burden of liver cirrhosis in mortality: results from the global burden of disease study","volume":"10","author":"Ye","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ejphar.2024.177077_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"Yu","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejphar.2024.177077_bib52","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/hep.32392","article-title":"Letter to the editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?","volume":"76","author":"Zanetto","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2024.177077_bib53","doi-asserted-by":"crossref","first-page":"12626","DOI":"10.1021\/acs.jmedchem.2c00660","article-title":"Discovery and optimization of the first highly effective and orally available galectin-3 inhibitors for treatment of fibrotic disease","volume":"65","author":"Zetterberg","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2024.177077_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/cmdc.201700744","article-title":"Monosaccharide derivatives with low-nanomolar lectin affinity and high selectivity based on combined fluorine-amide, phenyl-arginine, sulfur-\u03c0, and halogen bond interactions","volume":"13","author":"Zetterberg","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejphar.2024.177077_bib55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ab.2004.06.042","article-title":"Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions","volume":"334","author":"S\u00f6rme","year":"2004","journal-title":"Anal. Biochem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924007672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924007672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T01:28:15Z","timestamp":1733621295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924007672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":55,"alternative-id":["S0014299924007672"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177077","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177077"}}